EXPERT OPINION

Rational Deprescribing Practices in Elderly Patients: An Expert Opinion

Shambo S Samajdar[1], Nandini Chatterjee[2], Jyotirmoy Pal[3], Melvin George[4], Sougata Sarkar[5], Sumalya Sen[6], Shatavisa Mukherjee[7], Shashank R Joshi[8], Sanjay Bandyopadhyay[9], Shailendra Handu[10], Santanu K Tripathi[11], Arvind Mathur[12], Meenaxi Sharda[13]

Abstract

Background: The prevalence of polypharmacy and hyperpolypharmacy in India is a growing concern, particularly among the elderly. With over 49% of the elderly population engaged in polypharmacy and 31% in hyperpolypharmacy, the resultant issues of potentially inappropriate medications (PIMs) are increasingly evident. These medications, often unnecessary, can lead to severe adverse effects, diminishing the quality of life for a significant portion of this demographic. Addressing these issues is imperative for enhancing healthcare outcomes and necessitates the development of deprescribing guidelines that cater specifically to the Indian healthcare context.

Objective: This opinion aims to provide a structured approach to deprescribing, targeting the minimization of risks associated with unnecessary medication use among the elderly in India. The primary goal is to establish evidence-based, practical guidelines adaptable to diverse healthcare settings across the country, ensuring both safety and efficacy in medication management.

Methods: The development of this opinion involved a comprehensive interdisciplinary approach, incorporating inputs from clinical pharmacologists, geriatricians, internal medicine experts, endocrinologists, gastroenterologists, cardiologists, primary care physicians, pharmacists, and patient advocacy groups. An expert panel was formed to conduct extensive literature reviews, ensuring a robust evidence base for the opinion development. Consensus meetings were held to harmonize expert opinions and integrate clinical practices with empirical evidence. Pilot testing in various healthcare settings, both urban and rural, was crucial for evaluating the practicality and effectiveness of the guidelines. Feedback from these tests was used to refine the guidelines further, ensuring their relevance and applicability across different regions and healthcare systems within India.

Results: The opinion outlines a systematic approach to deprescribing, including the identification of PIMs through validated tools like the Beers and STOPP/START criteria. They emphasize the importance of assessing individual patient risks, such as drug-drug and drug-disease interactions, before initiating any changes to medication regimens. A key component is the implementation of a patient-centered care model, emphasizing shared decision-making between healthcare providers and patients. This approach is expected to foster better patient engagement and compliance. The anticipated impact of these guidelines includes a reduction in adverse drug events, increased medication adherence, and overall improvement in the health and well-being of the elderly population.

Conclusion: The opinions presented are poised to transform prescribing practices across India by reducing unnecessary medication use among the elderly. By focusing on evidence-based interventions, patient-specific considerations, and collaborative care approaches, these guidelines are expected to mitigate the risks associated with polypharmacy and enhance the quality of life for older adults. The successful implementation of these guidelines requires ongoing education and support for healthcare providers, as well as regular updates based on emerging evidence and clinical outcomes.

Keywords: Deprescribing, Expert opinion, Geriatric care, India, Patient safety, Polypharmacy.

Bengal Physician Journal (2024): 10.5005/jp-journals-10070-8072

Introduction

Background

Polypharmacy, defined as the concomitant use of five to nine medications, and hyperpolypharmacy, defined as the use of ten or more medications, are increasingly prevalent among the elderly population in India. The rising burden of chronic diseases among older adults necessitates complex medication regimens, leading to significant polypharmacy rates. A systematic review and meta-analysis revealed that approximately 49% of older Indian adults are affected by polypharmacy, while hyperpolypharmacy impacts 31% of this population.[1] These figures underscore the widespread use of multiple medications among the elderly, raising concerns about the potential for inappropriate prescribing practices. Potentially inappropriate medications (PIMs) are particularly concerning, with 28% of older adults in India reported to be on PIMs, which can lead to adverse drug reactions (ADRs) and diminished quality of life.[1]

[1]Independent Clinical Pharmacologist and Consultant Physician, Diabetes and Allergy-Asthma Therapeutics Specialty Clinic, Kolkata, West Bengal, India

[2]Department of General Medicine, IPGMER and SSKM Hospital, Kolkata, West Bengal, India

[3]Department of General Medicine, Sagor Dutta Medical College and Hospital, Kolkata, West Bengal, India

[4]Department of Clinical Pharmacology, SRM Medical College and Hospital, Chennai, Tamil Nadu, India

[5]Department of Clinical and Experimental Pharmacology, School of Tropical Medicine, Kolkata, West Bengal, India

[6]Department of Pharmacology, Gouri Devi Institute of Medical Sciences and Hospital, Durgapur, West Bengal, India

[7]Department of Clinical and Experimental Pharmacology, School of Tropical Medicine, Kolkata, West Bengal, India

[8]Department of Endocrinology, Joshi Clinic, Mumbai, Maharashtra, India

Regional variations exist, with North-East India experiencing a polypharmacy prevalence of 65%, while hyperpolypharmacy is notably higher in South India at 33%. The use of PIMs is also unevenly distributed, with prevalence rates ranging from 17.8% in Northern India to 33% in the West.[1] The adverse impacts of polypharmacy are further highlighted by its association with increased anticholinergic burden and cardiac autonomic neuropathy among community-dwelling elderly patients. A study conducted in Kolkata, India, revealed that 26.6% were on polypharmacy. The study found that the anticholinergic burden, which refers to the cumulative effect of taking multiple medications with anticholinergic properties, was significantly higher among patients on polypharmacy and was associated with a higher incidence of cardiac autonomic neuropathy, a condition characterized by dysfunction in the autonomic nervous system, affecting cardiovascular health.[2]

These observations underscore the clinical significance of managing polypharmacy to mitigate risks of serious adverse outcomes such as cardiac autonomic dysfunction.

Also, these studies highlight the critical need for tailored interventions and guidelines to promote rational geriatric prescribing practices in India, aiming to reduce medication-related risks and enhance the overall health and well-being of older adults. Addressing polypharmacy through deprescribing and other strategies is essential to improving clinical outcomes and quality of life in this vulnerable population.

Challenges

India's healthcare system faces numerous challenges related to medication management, exacerbating issues of polypharmacy, inappropriate prescribing, and medication misuse. One of the most significant challenges is the dominance of the private sector in healthcare delivery, which accounts for approximately 75% of healthcare expenditures coming directly from households' out-of-pocket expenses. This financial burden often leads to catastrophic healthcare costs, pushing many families into poverty.[3] The lack of regulation in the private sector results in significant variations in the quality and cost of services, contributing to inequitable access to healthcare.[3,4]

While the public sector provides healthcare services at low or no cost, it is often perceived as unreliable and of inferior quality, which deters many individuals from seeking care unless they cannot afford private options.[3] This perception and reality of varying quality levels complicate medication management, as the lack of consistent standards leads to a wide disparity in prescribing practices.

Another critical challenge is the overuse and misuse of medications, particularly antibiotics, in India. Studies have demonstrated that antibiotic overuse is prevalent across various regions, with pharmacists frequently dispensing antibiotics without prescriptions.[5–7] This practice contributes to antibiotic resistance and poses a significant public health risk. For example, a study in Vellore found extensive antibiotic overuse among service providers, with a large proportion of prescriptions being unnecessary.[5]

Polypharmacy is also widespread, with many patients receiving more medications than clinically indicated, often due to prescribing by brand names instead of generic alternatives.[8] This tendency increases healthcare costs and the risk of ADRs. The literature reveals a high prevalence of ADRs, particularly among older adults with multiple comorbidities and those experiencing longer hospital stays.[9] Contributing factors include poor prescribing practices and a lack of compliance with medication regimens.[8]

Furthermore, there is a notable issue with the lack of ADR reporting. Studies indicate that the low reporting rate is due to a lack of knowledge about the reporting process, time constraints, and fears of legal repercussions.[8] This underreporting impedes efforts to identify and address medication-related problems effectively.

Addressing these challenges requires a multifaceted approach that includes regulatory reforms, increased government investment in healthcare, and initiatives to promote rational prescribing practices. Scaling up government expenditure on health could provide the necessary infrastructure boost, especially in rural and marginalized areas.[4]

Rationale

The growing prevalence of polypharmacy and medication misuse among older adults in India highlights the urgent need for deprescribing guidelines tailored to the Indian healthcare context. In India, the rapid aging of the population and the rising burden of chronic diseases have led to increased medication use, often resulting in polypharmacy and the use of PIMs.[1–3,8] This is compounded by a healthcare system dominated by the private sector, where 75% of healthcare expenses are out-of-pocket, causing significant financial strain on families.[1] The lack of regulation and standardization in prescribing practices exacerbates these issues, contributing to medication-related harm and ADRs. Globally, it has been observed that up to half of the medications used by frail older patients in residential aged care facilities are preventive in nature and often inappropriate or futile at the end of life.[10] This scenario is similarly applicable in India, where there is regularly a disconnect between prescribed medications and the current health status and needs of elderly patients.[11]

Structured guides to deprescribing, which include algorithms and flowcharts, can aid clinicians in systematically reviewing and discontinuing medications that are no longer necessary or potentially harmful.[10] In the Indian context, this opinion would provide a framework for healthcare providers to evaluate and optimize medication regimens, ensuring they align with the patient's current health needs and circumstances.

[9]Department of Gastroenterology, ILS Hospital, Dumdum, Kolkata, West Bengal, India

[10]Department of Pharmacology, AIIMS, Rishikesh, Uttarakhand, India

[11]Department of Pharmacology, JIMS, Kolkata, West Bengal, India

[12]Director and Managing Trustee, Asian Centre for Medical Education, Research and Innovation, Jodhpur, Rajasthan, India

[13]Department of Geriatric Medicine, Government Medical College, Kota, Rajasthan, India

Corresponding Author: Shatavisa Mukherjee, Department of Clinical and Experimental Pharmacology, School of Tropical Medicine, Kolkata, West Bengal, India, Phone: +91 9830529192, e-mail: shatavisa100@gmail.com

How to cite this article: Samajdar SS, Chatterjee N, Pal J, *et al.* Rational Deprescribing Practices in Elderly Patients: An Expert Opinion. Bengal Physician Journal 2024;11(3):133–145.

Source of support: Nil

Conflict of interest: None

The most important principle in implementing this opinion should be the mantra "NO NAME, NO SHAME, NO BLAME". This approach encourages an open, non-punitive environment where healthcare providers can critically evaluate prescribing practices without fear of retribution or embarrassment. By focusing on improving patient outcomes rather than assigning blame, the guidelines promote a culture of safety and continuous improvement in medication management. This principle supports collaborative decision-making, allowing healthcare providers to work together with patients and caregivers to tailor medication regimens that are both effective and appropriate for the individual's current health status and goals. By fostering a system where learning and adaptation are prioritized, these guidelines aim to significantly enhance the quality of care for older adults in India, ultimately leading to better health outcomes and reduced healthcare costs.

Opinion

Identifying Potentially Inappropriate Medications (PIMs)

Identifying PIMs is a crucial first step in the deprescribing process. Potentially inappropriate medications are medications where the potential risks outweigh the benefits, particularly in older adults who are more susceptible to ADRs due to age-related changes in pharmacokinetics and pharmacodynamics. The identification of PIMs involves using standardized screening tools and conducting comprehensive medication reviews (CMRs) to optimize medication regimens and improve patient outcomes.

Use of Screening Tools

Beers Criteria[12]

The Beers criteria, developed by the American Geriatrics Society, is one of the most widely used tools for identifying PIMs in older adults. It provides a list of medications that are potentially inappropriate for use in older populations, based on their association with an increased risk of adverse effects.

Key features: The Beers criteria categorize medications into different lists based on *the type of risk they pose, such as medications to avoid regardless of condition, medications to avoid in certain diseases or syndromes, and medications to use with caution*. It also provides recommendations for alternative therapies when available.

Application in practice: Healthcare providers can use the Beers Criteria as a reference during medication reviews to identify medications that may no longer be appropriate for older adults. For example, medications with strong anticholinergic properties, such as diphenhydramine, are included in the list due to their potential to cause confusion, dry mouth, constipation, and urinary retention in elderly patients.

STOPP/START Criteria[13]

The Screening Tool of Older People's Prescriptions (STOPP) and the Screening Tool to Alert Doctors to the Right Treatment (START) provide a complementary approach to identifying PIMs and prescribing omissions.

STOPP criteria: This tool helps identify medications that are potentially inappropriate based on physiological changes in older adults and the risk of drug-drug and drug-disease interactions. For instance, the use of long-term benzodiazepines for anxiety in elderly patients is discouraged due to the risk of sedation and falls.

START criteria: In contrast, the START criteria focus on identifying therapeutic gaps where patients are not receiving medications that are clinically indicated for their conditions. For example, it alerts healthcare providers to consider statins for older adults with a history of coronary artery disease unless contraindicated.

Clinical use: The STOPP/START criteria can be used in conjunction with the Beers criteria to provide a more comprehensive assessment of medication appropriateness. This approach ensures that clinicians not only identify PIMs, but also address under treatment by ensuring that necessary medications are not omitted.

Comprehensive Medication Review Process

A CMR is an in-depth evaluation of a patient's medication regimen with the goal of identifying PIMs, optimizing therapy, and improving patient outcomes. This process involves several key steps:

(A) Medication Reconciliation

Objective: Ensure that the medication list is accurate and complete by verifying the medications, doses, and frequencies with the patient and cross-referencing with their medical records.

Process: Engage patients in reviewing their medication lists, including prescription drugs, over-the-counter medications, supplements, and herbal products. Identify any discrepancies, such as duplicate therapies or omissions, and reconcile them with the healthcare team.

(B) Assessment of Medication Indications and Effectiveness

Objective: Evaluate each medication for its current indication and therapeutic effectiveness. Determine if the medication is still necessary and if it achieves the desired outcomes.

Considerations: Assess whether the patient's condition or therapeutic goals have changed and whether there are more effective or safer alternatives. For example, long-term proton pump inhibitor use should be reassessed for patients who no longer have indications such as peptic ulcer disease or chronic gastroesophageal reflux disease.

(C) Evaluation of Adverse Effects and Drug Interactions

Objective: Identify any adverse effects or drug-drug interactions that may be harmful or contribute to new symptoms. This includes assessing the cumulative effect of medications with similar side effect profiles.

Tools: Utilize tools like the Anticholinergic Burden Scale to evaluate the cumulative anticholinergic effect, which can impair cognitive function and increase fall risk in older adults.

(D) Assessment of Adherence and Patient Preferences

Objective: Evaluate patient adherence to the medication regimen and understand any barriers they may face, such as complexity of the regimen, cost, or side effects.

Approach: Engage patients in discussions about their medication experiences and preferences. This includes understanding their

goals and aligning the medication plan with their values and lifestyle.

(E) Documentation and Follow-up

Objective: Document the findings of the medication review, including any changes made to the regimen, the rationale for those changes, and the anticipated outcomes.

Plan: Establish a follow-up plan to monitor the effects of any changes and address any new concerns that may arise. Regular follow-ups help ensure the medication regimen remains optimal over time.

In conclusion, the identification of PIMs is a foundational step in the deprescribing process, critical for enhancing patient safety and optimizing therapeutic outcomes, particularly among the elderly in India.

The application of screening tools such as the Beers Criteria and STOPP/START Criteria offers healthcare providers a robust framework for evaluating medication appropriateness. These tools facilitate the identification of both PIMs and under treatment, ensuring that medication regimens are tailored to the unique needs of each patient.

The CMR process proposed as clinical pharmacological reconciliation, review and feedback (CPRRF) further supports this effort. It enables a detailed assessment of medication indications, effectiveness, and potential adverse effects, while actively engaging patients in discussions about their treatment preferences and adherence challenges.[14,15]

Physicians and clinical pharmacologists play a pivotal role in this process of CPRRF by leveraging their expertise to evaluate and deprescribe unnecessary or inappropriate medications, thereby reducing the risk of ADRs and enhancing patient outcomes. Their involvement is particularly crucial for the elderly population at risk of polypharmacy and associated complications such as anticholinergic burden and cardiac autonomic neuropathy.

A recent study has underscored the effectiveness of clinical pharmacology consultations in increasing patient awareness of self-care practices and reducing drug-drug interactions, highlighting the importance of integrating these principles into modern healthcare.[16]

Risk Assessment

Effective risk assessment in deprescribing involves evaluating drug-drug interactions, drug-disease interactions, and considering cumulative effects alongside patient-specific factors. This comprehensive approach helps in minimizing potential adverse outcomes and optimizing therapeutic efficacy, particularly in older adults who often have complex medication regimens.

Evaluation of Drug-drug and Drug-disease Interactions

Drug-drug interactions occur when the pharmacological effects of one medication are altered by the presence of another. Drug-disease interactions happen when a medication exacerbates a patient's existing medical condition. Both types of interactions can lead to increased morbidity, especially in older adults who are more likely to be on multiple medications for various comorbidities.

Methods for Evaluation

- Medication review: Regular CMRs are crucial. These involve assessing the entire medication regimen to identify potential interactions and adjust prescriptions accordingly. This review should incorporate patient history, existing health conditions, and all current medications, including over-the-counter drugs and supplements.
- Clinical decision support systems (CDSS): Utilizing technology to support decision-making in prescribing practices can alert healthcare providers to potential interactions at the point of care.[14,17,18]
- Consultation with clinical pharmacologists: Involving clinical pharmacologists (DM Clinical Pharmacology) or in absence of clinical pharmacologist, pharmacologist with basic medical degree in the healthcare team can provide additional expertise in identifying and managing drug-drug and drug-disease interactions. They can offer insights into alternative therapies and assist in optimizing medication regimens.[15,18]

Consideration of Cumulative Effects and Patient-specific Factors

Cumulative effects refer to the overall impact of multiple medications on a patient's health, considering pharmacokinetics and pharmacodynamics. Patient-specific factors include age, weight, kidney and liver function, genetic factors, and individual health goals.

Cumulative Effects

- Anticholinergic burden: A high anticholinergic burden can lead to cognitive impairment, confusion, and increased risk of falls, particularly in older adults. Tools such as the Anticholinergic Burden Scale can help evaluate the cumulative anticholinergic effect of a patient's medication regimen.[19,20]
- Sedative load: Similar to the anticholinergic burden, the cumulative sedative load should be assessed to prevent excessive sedation, which can impair mobility and cognitive function. This assessment is particularly relevant in patients on multiple medications with sedative properties.[21]

Patient-specific Factors

- Comorbidities: The presence of multiple chronic diseases can affect how medications interact with each other and with the body. Risk assessment should consider how each medication aligns with the patient's overall health profile.
- Functional status: Evaluating the patient's functional status, including cognitive and physical capabilities, is crucial. Medications should be aligned with the patient's ability to manage their regimen and with their lifestyle. For instance, consider an elderly patient who is prescribed multiple medications for conditions like hypertension, diabetes, dyslipidemia, and osteoarthritis. The original regimen involves taking several pills at different times of the day. The patient finds it challenging to remember the timing and often misses doses, leading to poor control of blood pressure and blood sugar levels. To align the medication plan with the patient's ability to manage it, the prescribing physician could:
  - Consolidate dosing times: Adjust the schedule so that medications are taken at the same time each day, such as morning and evening, to reduce confusion.
  - Use combination medications: Where possible, switch to combination pills (e.g., a single pill containing both a blood pressure medication and a statin) to decrease the number of pills the patient needs to take.

  - Switch to once-daily formulations: Replace medications that require multiple daily doses with once-daily alternatives, if available and effective, to simplify the regimen.
  - Use medication aids: Recommend using a pill organizer or setting up reminders on a mobile device to help the patient remember to take their medications.
- Patient Preferences and Goals: Engaging patients in shared decision-making ensures that their preferences and health goals are considered. This collaborative approach helps align treatment plans with what patients value most in their care.[11,14–16] While concerns about engaging patients in shared decision-making in India may arise due to illiteracy rates, this barrier can be effectively addressed through culturally sensitive communication strategies and patient-centered approaches. Illiteracy does not equate to a lack of understanding or inability to participate in healthcare decisions. By using simple language, visual aids, and local dialects, healthcare providers can convey complex medical information in a way that is accessible and comprehensible. Additionally, involving family members, who often play a crucial role in healthcare decisions in India, can help bridge gaps in understanding. By actively listening to the patient's concerns and values, even those with limited formal education can express their preferences and priorities. This collaborative approach ensures that treatment plans are aligned with what patients value most in their care, leading to better adherence and outcomes. The success of shared decision-making in such contexts lies in the healthcare provider's ability to adapt their communication style and engage the patient and family members meaningfully in the care process.

Strategies for Risk Assessment

- Risk scoring systems: Implementing risk scores, such as the GerontoNet ADR risk score, helps estimate the likelihood of ADRs based on patient-specific factors such as age, comorbidities, and renal function.[22]
- Regular monitoring and follow-up: Continuous monitoring of the patient's response to medication changes and regular follow-ups are essential to adapt treatment plans as needed and to prevent adverse events.

A thorough risk assessment process that incorporates evaluations of drug-drug and drug-disease interactions, as well as patient-specific factors and cumulative effects, is essential for optimizing medication regimens. By using a patient-centered approach and leveraging available tools and resources, healthcare providers can enhance patient safety and improve therapeutic outcomes in older adults.

Patient-centered Approach

Strategies for Shared Decision-making

Shared decision-making is a collaborative process that involves healthcare providers and patients working together to make decisions about the patient's care. In the context of deprescribing, this approach is critical to ensuring that patients' preferences, values, and needs are considered, leading to more personalized and acceptable medication plans.

(A) Engagement and Communication

Patient involvement: Encouraging patients to actively participate in their healthcare decisions fosters a sense of ownership and empowerment. Clinicians should facilitate open discussions about the risks and benefits of medications, emphasizing that the goal is to optimize health outcomes and minimize harm.

Building trust: Establishing a trusting relationship between patients and healthcare providers is essential for effective shared decision-making. This involves listening to patients' concerns, respecting their autonomy, and providing information transparently and empathetically.[23]

(B) Information Sharing

Education on medication effects: Patients should be informed about how medications affect their bodies, especially as they age, which may necessitate changes in medication regimens. Discussions should include potential side effects, interactions, and the possibility of ADRs.

Exploration of alternatives: Presenting alternative treatment options, including non-pharmacological approaches, allows patients to consider various pathways to managing their health conditions. This can include lifestyle changes, dietary modifications, or the use of supplements.[14,23]

(C) Decision Aids

Utilization of decision aids: Tools such as decision aids can help patients understand their options and the potential outcomes of continuing, reducing, or stopping medications. These aids can be brochures, charts, or digital applications that visually represent information.

Collaborative goal setting: Working with patients to set realistic and achievable health goals is an integral part of the decision-making process. This ensures that the deprescribing plan aligns with the patient's life goals and expectations.

Individualized Care Planning

Individualized care planning tailors medical interventions to the unique needs and circumstances of each patient. This approach recognizes that each patient's health journey is different and requires personalized strategies to achieve optimal outcomes.[14]

(A) Comprehensive Assessment

Holistic evaluation: Assessing a patient's overall health status, including their physical, mental, and social well-being, provides a complete picture necessary for personalized care planning. This includes understanding the patient's lifestyle, social support systems, and health literacy.

Risk-benefit analysis: Evaluating the potential risks and benefits of each medication in the context of the patient's current health status is crucial. Factors such as comorbidities, life expectancy, and functional abilities should guide the deprescribing process.

(B) Tailored Interventions

Customized medication plans: Adjusting medication regimens based on individual patient factors, such as genetics, preferences, and responses to treatment, ensures that each patient receives the most appropriate care. This includes dose adjustments, substitution with safer alternatives, or discontinuation.

Monitoring and follow-up: Regular monitoring of patient outcomes and ongoing communication are essential components of individualized care. This allows for timely adjustments to the care plan and addresses any emerging issues, such as withdrawal symptoms or the recurrence of symptoms.[23]

(C) Patient and Caregiver Involvement

Collaborative care models: Involving caregivers and family members in the care process can enhance support and adherence to deprescribing plans. Their insights and observations can provide valuable information about the patient's response to medication changes.

Empowerment and education: Empowering patients and caregivers with knowledge about medication management promotes adherence and proactive health management. Educational initiatives should focus on recognizing ADRs, understanding medication labels, and the importance of adherence.[14,23]

A patient-centered approach to deprescribing emphasizes the importance of shared decision-making and individualized care planning. By actively involving patients in their healthcare decisions and tailoring interventions to their specific needs, healthcare providers can improve patient outcomes, enhance satisfaction, and ensure the safe and effective use of medications. This approach aligns with the broader goals of deprescribing to minimize medication burden and optimize therapeutic benefits.

Prioritization Framework for Deprescribing

Criteria for Prioritizing Medications for Deprescription

The process of deprescribing involves the careful evaluation of a patient's medication regimen to identify PIMs and prioritize those that should be discontinued or adjusted. The prioritization framework for deprescribing is essential to optimize patient safety and enhance therapeutic outcomes.[24] The following criteria are crucial in determining which medications should be prioritized for deprescription:

- Potential for harm: Medications that pose a high risk of adverse effects, particularly in vulnerable populations such as the elderly, should be prioritized for review. This includes drugs with a high anticholinergic burden, sedative properties, or those that increase the risk of falls, cognitive impairment, or cardiovascular events.
- Lack of indication: Medications that are not supported by a clear clinical indication or whose therapeutic goals have been achieved should be considered for discontinuation. This includes medications prescribed for conditions that are no longer present or for symptoms that have resolved.
- Redundancy: Medications with overlapping mechanisms of action or therapeutic effects should be assessed for redundancy. This often occurs when multiple medications are prescribed for the same condition, leading to unnecessary polypharmacy.
- Patient preference and quality-of-life: Patient-centered care involves considering the patient's preferences and quality of life when making deprescribing decisions. Medications that adversely affect a patient's quality of life or do not align with their treatment goals should be prioritized for discontinuation.
- Drug-drug and drug-disease interactions: Medications that have significant interactions with other drugs or exacerbate existing medical conditions should be reviewed. This includes drugs that may worsen comorbid conditions or interact negatively with other therapies.
- Pharmacoeconomic considerations: The cost of medications should be considered, especially for elderly patients who may have limited financial resources. When a less expensive but equally effective alternative is available, it should be prioritized to reduce the economic burden. Deprescribing or switching to cost-effective options can help manage healthcare expenses, making treatments more accessible and sustainable for patients who live frugally due to limited savings or cash flow. This approach aligns with patient-centered care by considering the financial impact of medication regimens on the patient's overall quality of life (Appendix A, B).

Process for Prioritization Based on Risk and Benefit Analysis

The prioritization process for deprescribing involves a systematic assessment of the risks and benefits associated with each medication. The following steps outline the process for prioritization:

- Medication reconciliation: Conduct a comprehensive review of the patient's current medication list, including prescription drugs, over-the-counter medications, and supplements. This step ensures that all medications are accounted for and provides a basis for further evaluation.
- Risk assessment: Evaluate the risk associated with each medication, considering factors such as the patient's age, renal and hepatic function, and comorbidities. Tools like the anticholinergic burden calculator and risk scales can aid in assessing the cumulative risk associated with multiple medications.
- Benefit analysis: Assess the therapeutic benefits of each medication in the context of the patient's current health status and treatment goals. Consider whether the medication achieves its intended outcomes and whether alternative therapies might offer a better risk-benefit profile.
- Clinical judgment and shared decision-making: Engage the patient and their caregivers in the decision-making process. Discuss the risks and benefits of continuing or discontinuing each medication, considering the patient's preferences and values.
- Implementation and monitoring: Once a decision is made to discontinue or adjust a medication, implement a tapering plan if necessary and monitor the patient for withdrawal symptoms or changes in their condition. Regular follow-ups are essential to ensure the safety and efficacy of the deprescribing process.
- Documentation: Document the rationale for deprescribing decisions, including the anticipated outcomes and any discussions with the patient. This documentation is vital for continuity of care and for communicating with other healthcare providers involved in the patient's care.

By employing a structured prioritization framework, healthcare providers can effectively manage polypharmacy and reduce the risk of adverse drug events. This approach not only enhances patient safety but also improves the overall quality of care by ensuring that medication regimens are aligned with the patient's current health needs and treatment goals.[14,15,23,24]

Tapering and Monitoring Protocols

Effective deprescribing requires careful planning and monitoring to ensure patient safety and improve outcomes. This section provides guidelines for the safe tapering of medications and outlines strategies for monitoring and follow-up during the deprescribing process.[25]

Process of Safe Tapering of Medications[25–27]

- Assess the need for tapering:
  - Before initiating tapering, evaluate whether tapering is necessary based on the patient's current health status,

risk of withdrawal symptoms, and overall treatment goals. Consider the pharmacokinetics and pharmacodynamics of the medication, particularly for those with a long half-life or those that are highly potent.
  - Medications that commonly require tapering include benzodiazepines, antidepressants, antipsychotics, and corticosteroids due to the risk of withdrawal symptoms or rebound effects.
- Develop a tapering schedule:
  - Create a tapering schedule tailored to the individual patient, considering factors such as the dosage, duration of use, and patient's response to previous tapering attempts.
  - Start with a small reduction in dose, typically 10 to 25% of the current dose, and adjust based on patient tolerance and response.
  - Allow sufficient time between dose reductions to monitor for withdrawal symptoms and to allow the patient to adjust physiologically and psychologically.
- Monitor for withdrawal symptoms:
  - Educate patients and caregivers about potential withdrawal symptoms and encourage them to report any adverse effects promptly.
  - Common withdrawal symptoms may include anxiety, insomnia, agitation, and physical symptoms such as nausea or dizziness.
  - Adjust the tapering schedule if significant withdrawal symptoms occur, possibly slowing the rate of tapering or pausing to stabilize the patient.
- Patient education and support:
  - Engage patients in shared decision-making, ensuring they understand the reasons for tapering and are involved in the planning process.
  - Provide educational resources and support throughout the tapering process to improve adherence and confidence.

Monitoring Strategies and Follow-up Plans

- Regular monitoring visits:
  - Schedule regular follow-up visits to assess the patient's response to tapering, monitor for withdrawal symptoms, and make necessary adjustments to the tapering plan.
  - Use these visits to reassess the patient's overall medication regimen and address any new or ongoing health concerns.
- Use of monitoring tools:
  - Implement tools such as the Anticholinergic Burden Calculator or medication review checklists to identify potential risks and assess the effectiveness of the deprescribing process.
  - Consider using clinical informatics tools like the Geriatric Risk Assessment MedGuide (GRAM) for identifying and managing risks associated with polypharmacy.
- Interdisciplinary collaboration:
  - Collaborate with pharmacists, nurses, and other healthcare providers to ensure comprehensive care and support during the tapering process.
  - Engage in discussions with specialists when managing complex cases or when new medications are introduced.
- Patient feedback and adjustment:
  - Encourage patients to provide feedback about their experiences and any difficulties encountered during tapering.
  - Be prepared to adjust the tapering strategy based on patient feedback and clinical findings.
- Long-term follow-up:
  - After completing the tapering process, continue to monitor the patient's health status and medication regimen periodically to prevent the reintroduction of unnecessary medications.
  - Focus on maintaining an optimal medication regimen that aligns with the patient's current health needs and goals.

The process of tapering and monitoring medications during deprescribing is a patient-centered approach that requires careful planning, interdisciplinary collaboration, and ongoing evaluation to achieve safe and effective outcomes. Implementing these strategies will help mitigate the risks associated with polypharmacy and improve the quality of care for older adults.

Implementation Strategies

Implementing deprescribing guidelines effectively requires a comprehensive approach involving appropriate tools, educational programs, and strategies to overcome challenges and barriers. This section outlines the tools and resources developed to support guideline implementation, describes educational programs for healthcare providers, and discusses the challenges faced during implementation along with potential strategies to address them.

Tools and Resources

A variety of tools and resources have been developed to facilitate the implementation of deprescribing guidelines. These include decision support algorithms, educational pamphlets, and web-based resources designed to assist healthcare providers and patients in the deprescribing process.

Decision Support Algorithms

Decision support algorithms are central to the implementation of deprescribing guidelines. These algorithms provide healthcare providers with a step-by-step framework for evaluating and discontinuing PIMs. By integrating these algorithms into electronic health records (EHRs), clinicians can easily access them during patient consultations, ensuring that deprescribing considerations are part of routine care.

Educational Pamphlets and Web-based Resources

Educational pamphlets and web-based resources have been developed to inform patients about the benefits and processes of deprescribing. These materials aim to increase patient engagement and understanding, empowering them to participate actively in decision-making about their medications. Web-based resources also offer interactive tools, such as medication review checklists and risk assessment calculators, to assist both patients and healthcare providers in identifying medications suitable for deprescribing.

Integration with Clinical Practice Guidelines

Incorporating deprescribing recommendations within existing clinical practice guidelines is crucial for widespread adoption. By embedding these recommendations into standard care protocols, healthcare providers are more likely to consider deprescribing as part of their regular practice. Collaboration with guideline development organizations can facilitate this integration, ensuring that deprescribing is included in the treatment pathways for various conditions.

Educational Programs

Education and training programs are essential components of implementing deprescribing guidelines. These programs are designed to equip healthcare providers with the knowledge and skills needed to effectively carry out deprescribing in clinical practice.

Training Workshops and Seminars

Training workshops and seminars offer healthcare providers the opportunity to learn about the principles and practices of deprescribing. These sessions typically cover topics such as identifying PIMs, conducting CMRs, and engaging in shared decision-making with patients. By providing hands-on training and real-world scenarios, these programs enhance clinicians' confidence and competence in deprescribing.

Interprofessional Education (IPE)

Interprofessional education programs bring together healthcare providers from different disciplines to learn about deprescribing collaboratively. These programs emphasize the importance of teamwork and communication in the deprescribing process, highlighting the roles of various healthcare professionals, including physicians, pharmacists, nurses, and social workers, in optimizing medication use.

Online Learning Modules

Online learning modules offer flexible and accessible training options for healthcare providers. These modules provide comprehensive coverage of deprescribing concepts and practices, allowing clinicians to learn at their own pace. Interactive elements, such as quizzes and case studies, reinforce learning and provide opportunities for self-assessment.

Challenges and Barriers

Despite the availability of tools and educational programs, several challenges and barriers can hinder the implementation of deprescribing guidelines. Understanding these obstacles is critical to developing strategies to overcome them.

Cultural and Organizational Barriers

One of the primary challenges in implementing deprescribing guidelines is the existing culture within healthcare organizations that prioritizes prescribing over deprescribing. Many healthcare providers are accustomed to prescribing medications and may be resistant to discontinuing them, fearing potential negative outcomes or perceived challenges to their clinical judgment.

Lack of Time and Resources

Healthcare providers often face time constraints during patient consultations, making it difficult to conduct thorough medication reviews and engage in detailed discussions about deprescribing. Additionally, limited access to resources, such as clinical pharmacologists or decision support tools, can further impede the implementation process.

Fear of Negative Outcomes

Concerns about negative outcomes, such as withdrawal symptoms or the recurrence of medical conditions, can deter healthcare providers from deprescribing. This fear is compounded by a lack of robust evidence and clear guidelines on managing such outcomes, leading to hesitation in initiating deprescribing interventions.

Discussion

The discussion section of this opinion provides an overview of their anticipated impact on patient outcomes, a comparison with existing international deprescribing guidelines, and suggestions for future research and refinement.

Impact on Patient Outcomes

Implementing these deprescribing opinion is expected to significantly enhance patient safety and quality of life by optimizing medication regimens and reducing the risks associated with polypharmacy. The guidelines aim to achieve the following benefits:

- Reduction in Adverse Drug Events: By identifying and discontinuing PIMs, the guidelines aim to decrease the incidence of adverse drug events, which are particularly prevalent among older adults due to the complex nature of their medication regimens. Studies have shown that reducing polypharmacy can lower the risk of hospitalizations and emergency department visits.
- Improvement in Cognitive and Physical Function: Deprescribing medications that contribute to anticholinergic burden or have sedative properties can lead to improvements in cognitive and physical function, thereby enhancing the overall quality of life for older adults.
- Increased Patient Engagement and Satisfaction: By emphasizing patient-centered care and shared decision-making, the guidelines foster greater patient involvement in their healthcare. Engaged patients are more likely to adhere to treatment plans, experience improved outcomes, and report higher levels of satisfaction with their care.
- Optimized Medication Use: The guidelines encourage healthcare providers to regularly assess the appropriateness of medications, leading to more rational and targeted use of pharmacotherapy. This optimization can result in cost savings for both patients and healthcare systems by reducing unnecessary medication use and associated costs.

Comparison with International Guidelines

This opinion aligns with international deprescribing guidelines while also addressing specific considerations relevant to the Indian healthcare context:

- Beers Criteria and STOPP/START Criteria: The guidelines incorporate widely recognized tools such as the Beers Criteria and the STOPP/START Criteria, which are used globally to identify PIMs and optimize medication regimens. These tools are adapted to suit the needs of Indian patients, considering regional variations in disease prevalence and medication availability.
- Patient-centered Approaches: Like international guidelines, these guidelines emphasize the importance of shared decision-making and patient engagement. However, they place particular emphasis on culturally sensitive communication and the inclusion of family members in the decision-making process, reflecting the collectivist nature of Indian society.
- Focus on Affordability and Accessibility: The guidelines address the economic constraints faced by many Indian patients by encouraging the use of cost-effective therapies and promoting access to affordable medications. This focus on affordability distinguishes them from some international frameworks that may not prioritize economic considerations to the same extent.

Future Directions

To enhance the effectiveness and applicability of the deprescribing guidelines, several areas for future research and guideline refinement have been identified:

- Research on long-term outcomes: While current evidence supports the benefits of deprescribing in reducing adverse events and improving quality of life, more research is needed to evaluate the long-term outcomes of deprescribing interventions, particularly in diverse patient populations and healthcare settings.
- Development of tailored interventions: Future research should focus on developing and testing tailored deprescribing interventions that address specific patient characteristics, such as genetic factors, comorbidities, and personal preferences.
- Integration of technology: The integration of health information technology, such as electronic health records and decision support systems, can enhance the implementation and monitoring of deprescribing practices. Future work should explore the development of user-friendly digital tools that facilitate medication reviews and support shared decision-making.
- Education and training programs: Continued investment in education and training programs for healthcare providers is essential to ensure that deprescribing practices are effectively implemented. Future efforts should focus on expanding access to these programs and evaluating their impact on clinical practice.
- Policy and advocacy efforts: Engaging policymakers and stakeholders in discussions about the benefits of deprescribing can help drive systemic changes that support its integration into routine care. Advocacy efforts should aim to raise awareness of the importance of medication optimization and the role of deprescribing in improving patient outcomes.
- Expanding the workforce and sustaining deprescribing efforts: To implement deprescribing on a larger scale across India's vast elderly population, there is an urgent need to expand the pool of professionals skilled in this area. Currently, trained clinical pharmacologists at the DM and MD Internal Medicine, Geriatric Medicine, and Pharmacology trained in Clinical Pharmacological Reconciliation, Review, and Feedback (CPRRF) are limited. Primary care is often delivered by MBBS-trained physicians, alternate medicine specialists, and practitioners with varying levels of expertise. Enhancing the training and exposure of these groups to deprescribing practices is crucial. Furthermore, sustaining deprescribing efforts requires continuous follow-up to ensure that patients do not revert to inappropriate or redundant medication regimens upon returning to their usual healthcare providers. This calls for establishing mechanisms to monitor deprescribing outcomes and maintain communication across the healthcare continuum to support ongoing medication optimization.

The expert opinion outlined in this document provides a comprehensive framework for optimizing medication use and improving patient outcomes in India. By addressing both clinical and contextual factors, these articles offer a valuable tool for healthcare providers striving to enhance the safety and quality of care for their patients.

Conclusion

The implementation of deprescribing framework is a critical step toward improving patient safety and optimizing medication use, particularly in the context of India's rapidly aging population and the rising prevalence of chronic diseases. This document provides a comprehensive framework for healthcare providers to identify and manage PIMs, ensuring that medication regimens are both safe and effective.

Summary of Key Points

- Identification of PIMs: Utilizing tools such as the Beers Criteria and STOPP/START Criteria, healthcare providers can systematically identify PIMs and reduce the risks associated with polypharmacy. These tools facilitate the optimization of medication regimens, enhancing patient safety and improving outcomes.
- Risk assessment: By evaluating drug-drug and drug-disease interactions, as well as considering cumulative effects and patient-specific factors, healthcare providers can better understand the risks and benefits associated with each medication. This approach ensures that treatment plans are tailored to individual patient needs.
- Patient-centered approach: The guidelines emphasize shared decision-making and individualized care planning, fostering greater patient engagement and satisfaction. By involving patients in their care decisions, healthcare providers can better align treatment goals with patient preferences and values.
- Prioritization framework: A structured framework for prioritizing medications for deprescription based on risk and benefit analysis helps ensure that the most appropriate and effective treatments are maintained while minimizing unnecessary medication use.
- Tapering and monitoring: Safe tapering protocols and robust monitoring strategies are essential for minimizing withdrawal symptoms and ensuring successful deprescribing. These protocols help healthcare providers manage the transition from high-risk medications to safer alternatives effectively.
- Implementation strategies: The integration of tools, educational programs, and strategies to overcome challenges and barriers is vital for the successful implementation of deprescribing practices. By addressing these factors, healthcare providers can ensure that deprescribing becomes a routine part of patient care.

Importance of Deprescribing in Enhancing Patient Care in India

Deprescribing is a crucial component of patient-centered care, particularly in India, where the burden of polypharmacy and medication-related harm is significant. The guidelines outlined in this document provide a strategic approach to minimizing the risks associated with inappropriate medication use, ultimately enhancing the quality of life for patients.

By adopting these advices, healthcare providers can reduce the incidence of adverse drug events, improve patient outcomes, and promote a culture of rational prescribing. The focus on patient engagement and shared decision-making empowers patients to take an active role in their healthcare, leading to more personalized and effective treatment plans.

As the healthcare landscape in India continues to evolve, the importance of deprescribing in optimizing medication use and improving patient safety cannot be overstated. By prioritizing deprescribing as a key component of patient care, healthcare providers can contribute to the development of a more efficient, effective, and patient-centered healthcare system.

The successful implementation of these deprescribing guidelines has the potential to transform patient care in India,

ensuring that medication regimens are both safe and aligned with the health needs and goals of each individual.

Acknowledgments

The authors would like to thank Monkwriter (https://monkwriter.com/) for providing professional assistance in the scientific writing of this article.

References

1. Bhagavathula AS, Vidyasagar K, Chhabra M, et al. Prevalence of polypharmacy, hyperpolypharmacy and potentially inappropriate medication use in older adults in India: A systematic review and meta-analysis. front pharmacol 2021;12:685518. DOI: 10.3389/fphar.2021.685518.
2. Samajdar SS, Das S, Sarkar S, et al. Association between polypharmacy and cardiovascular autonomic function among elderly patients in an urban municipality area of Kolkata, India: A record-based cross-sectional study. Geriatrics (Basel) 2022;7(6):136. DOI: 10.3390/geriatrics7060136.
3. Balarajan Y, Selvaraj S, Subramanian SV. Health care and equity in India. Lancet 2011;377(9764):505–515. DOI: 10.1016/S0140-6736(10)61894-6.
4. Porter G, Grills N. Medication misuse in India: A major public health issue in India. Journal of Public Health 2016;38(2):e150–e157. DOI: 10.1093/pubmed/fdv072.
5. Chandy SJ, Thomas K, Mathai E, et al. Patterns of antibiotic use in the community and challenges of antibiotic surveillance in a lower-middle-income country setting: A repeated cross-sectional study in Vellore, South India. J Antimicrob Chemother 2013;68(1):229–236.
6. Salunkhe SD, Pandit VA, Dawane JS, et al. Study of over the counter sale of antimicrobials in pharmacy outlets in Pune, India: A cross sectional study. Int J Pharm Bio Sci 2013;4(2):616–622.
7. Rathnakar UP, Sharma NK, Garg R, et al. A Study on the sale of antimicrobial agents without prescriptions in pharmacies in an urban area in South India. Journal of Clinical & Diagnostic Research 2012;6(6):951–954. [online] Available from: https://www.jcdr.net/articles/pdf/2308/7%20-%204511_E(C)_PF1(R)_F(P)_PF(V)_PFA(P)_PF(R)_U(P).pdf.
8. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007;5(4):345–351. DOI: 10.1016/j.amjopharm.2007.12.002.
9. Basu S, Chatterjee M, Chandra PK, et al. Antibiotic misuse in children by the primary care physicians – An Indian experience. Niger J Clin Pract 2008;11(1):52–57. PMID: 18689140.
10. Hopcroft P, Peel NM, Poudel A, et al. Prescribing for older people discharged from the acute sector to residential aged-care facilities. Intern Med J 2014;44(10):1034–1037. DOI: 10.1111/imj.12553.
11. Todd A, Holmes HM. Recommendations to support deprescribing medications late in life. Int J Clin Pharm 2015;37(5):678–681. DOI: 10.1007/s11096-015-0148-6.
12. By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2023;71(7):2052–2081. DOI: 10.1111/jgs.18372.
13. O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: Version 3. Eur Geriatr Med 2023;14(4):625–632. DOI: 10.1007/s41999-023-00777-y.
14. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Intern Med 2015;175:827–834. DOI: 10.1001/jamainternmed.2015.0324.
15. Samajdar SS, Tripathi SK. Clinical pharmacological reconciliation, review, and feedback in ensuring patient safety: A Commentary. J Clin Pharmacol 2023;63(9):1074–1075. DOI: 10.1002/jcph.2285.
16. Samajdar SS, Mukherjee S, Sarkar S, et al. Clinical pharmacological consultation in optimizing diabetic patient care: A cross-sectional observational study. Bengal Physician Journal 2023;10(1):6–8. DOI: 10.5005/jp-journals-10070-8006.
17. Anderson K, Stowasser D, Freeman C, et al. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: A systematic review and thematic synthesis. BMJ Open 2014;4(12):e006544. DOI: 10.1136/bmjopen-2014-006544.
18. Samajdar SS, Mukherjee S, Tripathi SK, et al. Deprescribing for better patient outcomes in chronic long term care and role of clinical pharmacological review. J Assoc Physicians India 2021;69(11):11–12. PMID: 34781620.
19. Nishtala PS, Salahudeen MS, Hilmer SN. Anticholinergics: Theoretical and clinical overview. Expert Opin Drug Saf 2016;15(6):753–768. DOI: 10.1517/14740338.2016.1165664.
20. Saha D, Samajdar SS, Begum SA, et al. Anticholinergic burden in geriatric patients attending clinical pharmacology clinic—A descriptive cross-sectional study in Eastern India. J Indian Med Assoc 2022;120(10):39–43.
21. Taipale HT, Bell JS, Soini H, et al. Sedative load and mortality among residents of long-term care facilities: A prospective cohort study. Drugs Aging. 2009;26(10):871–881. DOI: 10.2165/11317080-000000000-00000.
22. Onder G, Petrovic M, Tangiisuran B, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: The GerontoNet ADR risk score. Arch Intern Med 2010;170(13):1142–1148. DOI: 10.1001/archinternmed.2010.153.
23. Endsley S. Deprescribing unnecessary medications: A four-part process. Fam Pract Manag 2018;25(3):28–32.
24. Iyer S, Naganathan V, McLachlan AJ, et al. Medication withdrawal trials in people aged 65 years and older: A systematic review. Drugs Aging 2008;25(12):1021–1031. DOI: 10.2165/0002512-200825120-00004.
25. Mistler LA, Mellman TA, Drake RE. A pilot study testing a medication algorithm to reduce polypharmacy. Qual Saf Health Care 2009;18(1):55–58. DOI: 10.1136/qshc.2007.024471.
26. Scott IA, Gray LC, Martin JH, et al. Minimizing inappropriate medications in older populations: A 10-step conceptual framework. Am J Med 2012;125(6):529–537.e4. DOI: 10.1016/j.amjmed.2011.09.021.
27. Samajdar SS, Mukherjee S, Sharma J, et al. Clinical pharmacological reconciliation, review, and feedback in elderly care: A transformative approach. J Indian Acad Geriatr 2024;20(3):150–153. DOI: 10.4103/jiag.jiag_31_24.

Appendices

Appendix A: Detailed Algorithms and Flowcharts for the Deprescribing Process

This appendix includes comprehensive algorithms and flowcharts designed to guide healthcare providers through the systematic process of deprescribing. These resources cater to the Indian healthcare context, reflecting the common medications used, prevalent diseases, and specific healthcare practices relevant to Indian patients.

Algorithm 1: Deprescribing Process Overview

Step 1: Ascertain all medications, including prescribed, over-the-counter, and traditional remedies commonly used in India.
Step 2: Identify high-risk medications specific to the Indian population, such as those with a high anticholinergic burden or those commonly implicated in adverse reactions.
Step 3: Utilize risk prediction tools modified for local demographic and health data to evaluate patient-specific risks and benefits.
Step 4: Apply a utility grid to classify medications:

Class A: Very effective with minimal toxicity (e.g., first-line antihypertensives like ACE inhibitors in non-pregnant adults).
Class B: Reasonably effective but some concerns about toxicity (e.g., non-steroidal anti-inflammatory drugs considering gastrointestinal risks).
Class C: Concerns about both effectiveness and toxicity (e.g., long-term use of sedatives in the elderly).
Class D: Minimal effectiveness and considerable potential for toxicity in most circumstances (e.g., long-term use of proton pump inhibitors without clear indications).

Step 5: Implement strategies for patient engagement and shared decision-making, reflecting a deep understanding of cultural nuances in treatment adherence and patient communication.

Box 1: Flowchart: Steps for implementing deprescribing

- Patient consultation: Discussing the potential for deprescribing, considering patient values and cultural aspects of medicine use in India.
- Medication review: Conducted with a focus on locally prevalent conditions and the typical polypharmacy patterns seen in Indian clinics.
- Decision making: Incorporating patient and family preferences, commonly a key component in Indian healthcare decisions.
- Follow-up: Regular monitoring, which includes local healthcare practices and available resources.

Appendix B: Educational Materials and Patient Information Leaflets

Educational materials and patient information leaflets included in this appendix are tailored to enhance understanding and involvement of Indian patients in the deprescribing process. These materials are designed to be culturally appropriate and are available in multiple Indian languages to ensure wide accessibility.

Patient Leaflet 1: Understanding Deprescribing

Explains the concept of deprescribing, its benefits, and how it can improve health outcomes, particularly in the context of chronic disease management prevalent in India.

Patient Leaflet 1: Understanding deprescribing

Title: Understanding the Need for Deprescribing Proton Pump Inhibitors (PPIs)

Introduction

Proton pump inhibitors (PPIs) are widely prescribed medications in India for conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and Helicobacter pylori-associated ulcers. While PPIs are effective and generally safe for short-term use, long-term use may lead to several risks and potential adverse events. This leaflet explains the concept of deprescribing, its benefits, and guides you on how to safely reduce or stop taking PPIs if you no longer need them.

Why consider deprescribing PPIs?

Reduced Side Effects: Long-term use of PPIs has been associated with risks such as bone fractures, kidney disease, and nutritional deficiencies. Reducing the dose or discontinuing PPIs can decrease these risks.

Effective Management: Many patients continue PPIs without a reevaluation of their initial gastrointestinal symptoms. Regular assessment can often reveal that lower doses or discontinuation do not worsen symptoms.

Cost-effectiveness: Reducing or stopping unnecessary PPIs can lower healthcare costs, particularly relevant in the Indian healthcare setting where out-of-pocket expenses are significant for many families.

How to Deprescribe PPIs?

Assessment: The first step is to assess the need for continued PPI therapy. This includes reviewing the original reason for prescribing the PPI and determining if those conditions still require treatment.

Tapering Strategy: If a PPI is deemed unnecessary, gradually reducing the dose rather than abrupt cessation is advisable to avoid rebound acid secretion. For instance, the dose can be halved for a few weeks, or the medication can be taken every other day before stopping completely.

Monitoring: Close monitoring for any return of symptoms is crucial. This can guide whether the PPI needs to be reintroduced at a lower dose or if alternative treatments might be more appropriate.

Alternatives to PPIs

Lifestyle Modifications: Dietary changes, weight management, and avoiding specific triggers can effectively manage mild GERD symptoms without the need for continuous medication.

H2 Blockers: Medications like ranitidine can be used during the tapering phase or as a less potent alternative to PPIs for symptom control.

When to Seek Medical Advice?

Discuss with your healthcare provider before making any changes to how you take your PPI.

If symptoms return or worsen during the deprescribing process, consult your doctor to adjust the treatment plan accordingly.

Safety and Support

It's important to have a support system and clear communication with your healthcare provider throughout the process of deprescribing. This ensures that any adjustments to medication are made safely and effectively.

Conclusion

Understanding deprescribing is vital for managing your health proactively. By reducing or discontinuing unnecessary medications like PPIs under medical guidance, you can improve your health

outcomes and reduce the risk of long-term side effects. Engage actively in your treatment decisions and ensure you're taking medications that are truly beneficial for your current health needs.

Patient Leaflet 2: Managing Common Withdrawal Symptoms

Provides information on identifying and managing withdrawal symptoms that may arise from deprescribing certain medications, with tips that are specific to medications widely used in India.

Patient Leaflet 2: Managing common withdrawal symptoms

Introduction

When reducing or stopping certain medications, especially those used for long periods, you may experience withdrawal symptoms. This leaflet provides guidance on identifying and managing these symptoms, particularly for medications frequently prescribed in India, such as benzodiazepines and proton pump inhibitors (PPIs).

Understanding withdrawal symptoms: Withdrawal symptoms can vary depending on the medication being reduced or discontinued. Commonly observed symptoms include:

- Benzodiazepines: Anxiety, insomnia, restlessness, and muscle spasms.
- Proton Pump Inhibitors (PPIs): Rebound acid hypersecretion, resulting in symptoms like heartburn and indigestion.
- Antidepressants: Dizziness, flu-like symptoms, irritability, and mood disturbances.
- Managing withdrawal symptoms

Tapering Off Gradually

- Benzodiazepines: Reduce the dose gradually over weeks or even months, depending on the duration of use. For instance, decrease the daily dose by 10–25% every 2–4 weeks.
- PPIs: Reduce the dosage gradually or alter the frequency of intake. For example, if taking daily, switch to every other day before completely stopping.

Supportive Therapies

- Behavioral support: Cognitive behavioral therapy (CBT) can help manage anxiety and insomnia associated with benzodiazepine withdrawal.
- Diet and lifestyle: For PPI withdrawal, dietary modifications such as avoiding spicy and acidic foods can help manage symptoms.

Medication Alternatives

- Benzodiazepines: Consider using non-habit-forming alternatives like melatonin under medical guidance for insomnia.
- PPIs: Antacids or H2 blockers like ranitidine may be used on an as-needed basis to manage acid reflux symptoms during the tapering phase.

Monitoring and Follow-up

Regular follow-ups with your healthcare provider are crucial to monitor progress and adjust the tapering schedule as needed.

Keep a symptom diary to track changes and discuss them during your appointments.

Institutional and Caregiver Support: Engaging family members and caregivers in the deprescribing process is essential, especially for elderly patients or those with significant anxiety about withdrawal. Support from loved ones can make managing withdrawal symptoms more manageable.

When to Seek Immediate Medical Attention: If you experience severe withdrawal symptoms such as high fever, severe psychiatric symptoms, or any signs of physical distress, contact your healthcare provider immediately. These symptoms can require prompt medical intervention.

Conclusion

Managing withdrawal symptoms effectively requires a well-planned approach, involving gradual reduction, supportive therapies, and close monitoring. By understanding what to expect and how to handle these changes, you can successfully navigate the deprescribing process with minimal discomfort and maximum safety. Remember, never alter your medication regimen without professional guidance.

Educational Brochure: Role of Family in Deprescribing

Outlines how family members can support the patient through the deprescribing process, emphasizing the role of family in healthcare decisions, which is a significant aspect of Indian culture.

Box 2: Educational brochure: role of family in deprescribing

Introduction

In the Indian cultural context, family plays a pivotal role in healthcare decisions. This brochure outlines how family members can actively support patients through the process of deprescribing, helping to ensure the success and comfort of transitioning away from certain medications.

How Families Can Help

(A) Understanding the process:
- Educate yourselves on why deprescribing is necessary—understand the health benefits and potential side effects of continuing versus discontinuing a medication.
- Familiarize yourselves with the potential withdrawal symptoms and how they can be managed.

(B) Providing Emotional Support:
- Offer reassurance and encouragement, as patients may feel anxious about stopping a medication they have used for a long time.
- Be patient and provide a listening ear. Sometimes, just knowing someone is there to listen can make a big difference.

(C) Assisting with Medication Management:
- Help manage the tapering schedule by reminding or assisting the patient with when and how to take their medication as prescribed during the deprescribing process.
- Keep track of any changes in symptoms and help communicate these to healthcare providers.

(D) Advocating for the Patient:
- Accompany the patient to doctor visits and be active in discussions about their care plan.
- Ask questions and seek clarifications from healthcare providers to ensure that decisions align with the patient's overall health goals and cultural values.

(E) Promoting Healthy Lifestyle Choices:
- Encourage and help implement lifestyle changes that can aid in managing symptoms that were previously managed by medications, such as dietary adjustments or increased physical activity.

Box 3: Provider Guide: communication strategies for deprescribing

Introduction

Effective communication is crucial when initiating deprescribing, especially in a diverse cultural setting like India where patients' understanding and perceptions about medications can vary widely.

Communication Strategies

(A) Use Simple, Clear Language:
- Avoid medical jargon. Explain deprescribing in simple terms that the patient and their family can understand.
- Consider the patient's primary language and use multilingual resources or interpreters if necessary.

(B) Engage in Shared Decision-making:
- Involve the patient and their family members in the decision-making process. Discuss the pros and cons of continuing versus discontinuing the medication.

Contd...

Box 3: *Contd...*

- Respect the patient's and family's perspectives and incorporate their input into the care plan.

(C) Cultural Sensitivity:

- Be mindful of cultural beliefs about medications and healthcare. Some cultures may view stopping a medication as negative or may have traditional beliefs influencing their views on modern medicine.
- Show respect for these beliefs and work with the patient and family to address any concerns in a culturally appropriate manner.

(D) Educational Materials:

- Provide written materials that patients and families can take home, which reiterate key points discussed during consultations.
- Ensure these materials are available in the local languages and are culturally tailored to increase comprehension and relevance.

(E) Follow-up and Continuous Support:

- Schedule follow-up visits to monitor the patient's progress and manage any arising issues.
- Encourage ongoing communication, allowing patients and families to reach out with questions or concerns as they adapt to changes in medication.

Family involvement enriches the deprescribing process, providing patients with the support needed to navigate changes in their medication regimen safely and effectively. By employing respectful, clear, and culturally aware communication strategies, healthcare providers can foster an environment where patients feel cared for and supported, significantly enhancing the success of deprescribing initiatives. Boxes 2 and 3 had depicted these strategies in brief.

These appendices serve as a practical extension of the deprescribing framework, providing tools and resources that are specifically adapted to the Indian healthcare setting. They are designed to support both healthcare providers and patients in navigating the complexities of deprescribing, with a strong emphasis on cultural sensitivity, patient safety, and the promotion of optimal medication practices.